1. Immunology/Inflammation
  2. Complement System
  3. ANX-M1 (Human IgG1)

ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1].

For research use only. We do not sell to patients.

ANX-M1 (Human IgG1)

ANX-M1 (Human IgG1) Chemical Structure

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1][2].

Isotype

Human IgG1 kappa

Recommend Isotype Controls
Species Reactivity

Human

IC50 & Target

C1q

 

In Vivo

ANX-M1 (7.5 μg/μL-100 mg/kg; intravitreal; single dose; intraperitoneal; days 0,4,8) protects against progressive retinal degeneration in C57BL/6J mice with photo-oxidative damage-induced retinal degeneration (with TUNEL+ photoreceptor cell death reduction, ONL thickness increase, ERG responses improvement, and serum complement hemolytic activity reduction of >50% for effective regimens)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (adult, postnatal day 60-90, equal numbers of male and female, photo-oxidative damage-induced retinal degeneration)[1]
Dosage: 7.5 μg/μL (intravitreal post-treatment); 7.5 μg/μL (intravitreal pre-treatment); 100 mg/kg (systemic)
Administration: intravitreal (single dose on day 7 or day 0); intraperitoneal (days 0,4,8)
Result: Significantly reduced TUNEL+ photoreceptor cell death at day 14 compared to IgG control (P < 0.05), significantly increased outer nuclear layer (ONL) thickness (P < 0.05), significantly improved rod a-wave and b-wave electroretinography (ERG) responses (P < 0.05, most pronounced at 1.9 log cd.s/m²), and significantly improved cone ERG responses (P < 0.05) with intravitreal post-treatment; showed no significant differences in TUNEL+ cell count, ONL thickness, IBA1+ cell count, or ERG responses compared to IgG control (P > 0.05) with intravitreal pre-treatment; reduced serum complement hemolytic activity by >50% at day 12 (P < 0.05) but showed no significant differences in TUNEL+ cell count, ONL thickness, IBA1+ cell count, or ERG responses compared to IgG control (P > 0.05) with systemic administration
Gene ID

712  [NCBI]

Accession
Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[ANX-M1 (Human IgG1)]

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ANX-M1 (Human IgG1)
Cat. No.:
HY-P991886
Quantity:
MCE Japan Authorized Agent: